Triapine
Triapine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lbel effet parfait signs of age appearance minimizer foundation spf 20 fm | OTC monograph final | 2019-12-03 |
| lbel effet parfait signs of age appearance minimizer foundation spf 20 fm claire 2 lbel effet parfait signs of age appearance minimizer foundation ... | OTC monograph final | 2021-07-29 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
205 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Whooping cough | D014917 | EFO_0000650 | A37.0 | 2 | — | 2 | 1 | 5 | 10 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 7 | 1 | — | 8 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | 5 | 1 | 1 | 7 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 3 | 1 | 1 | — | 6 |
| Diphtheria | D004165 | EFO_0005549 | A36 | 1 | — | 2 | 1 | — | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 1 | 1 | 2 | 4 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 1 | 3 | 4 |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | 2 | — | 3 |
| Tetanus | D013742 | EFO_0005593 | A35 | 1 | — | 1 | 1 | — | 3 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | 2 | 3 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 10 | 7 | 1 | — | — | 16 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | 1 | — | 11 | 14 |
| Neoplasms | D009369 | — | C80 | 8 | 2 | 1 | — | 2 | 12 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 4 | 5 | 1 | — | — | 10 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 5 | 1 | — | — | 10 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 7 | — | 1 | 9 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | — | 8 | 9 |
| Carcinoma | D002277 | — | C80.0 | 2 | 3 | 1 | — | 1 | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 7 | — | — | 7 |
| Adenocarcinoma | D000230 | — | — | 2 | 3 | 1 | — | 1 | 7 |
Show 37 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 5 | — | — | 1 | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 4 | 6 | — | — | — | 8 |
| Recurrence | D012008 | — | — | 4 | 3 | — | — | — | 7 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 4 | 3 | — | — | — | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 3 | 1 | — | — | — | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 2 | — | — | — | 4 |
| Syndrome | D013577 | — | — | 3 | 1 | — | — | 1 | 4 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 1 | 2 | — | — | — | 3 |
| Blast crisis | D001752 | — | — | 1 | 2 | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 3 |
Show 54 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | — | — | — | 2 | 3 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | 1 | — | — | — | 2 | 3 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 2 | — | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
| Gene rearrangement | D015321 | — | — | 1 | — | — | — | — | 1 |
| Trismus | D014313 | — | — | 1 | — | — | — | — | 1 |
| Tetany | D013746 | HP_0001281 | P71.3 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Show 24 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 8 | 8 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 5 | 5 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 3 | 3 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 3 | 3 |
| Intervertebral disc degeneration | D055959 | HP_0008419 | — | — | — | — | — | 2 | 2 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | — | — | — | — | 2 | 2 |
| Fasciitis | D005208 | HP_0100537 | M72.9 | — | — | — | — | 2 | 2 |
| Sprains and strains | D013180 | — | — | — | — | — | — | 2 | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 2 | 2 |
Show 95 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triapine |
| INN | — |
| Description | 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, also called Triapine) is substance of interest for the treatment of cancer. It is a thiosemicarbazone derivative of 3-aminopyridine-2-carboxaldehyde. It presents an N-N-S array of donor sites that strongly bind iron, robbing iron-containing enzymes of their prosthetic group.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=S)N/N=C/c1ncccc1N |
Identifiers
| PDB | — |
| CAS-ID | 143621-35-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL231616 |
| ChEBI ID | — |
| PubChem CID | 9571836 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use